// App-Quantinova.ai

610 : Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors

Researchers

Presenter

  • Kevin Harrington

Principal Investigators

  • Isla Leslie

  • Ari VanderWalde

  • Tawnya Bowles

  • Joseph Sacco

  • Anna Olsson-Brown

  • Jiaxin Niu

  • Katy Tsai

  • Jason Chesney

  • Bartosz Chmielowski

  • Adel Samson

  • Terence Rhodes

  • Gino In

  • Anna Pavlick

  • Trisha Wise-Draper

  • Miguel Sanmamed

  • Laxminarasimha Donthireddy

  • Yawei Zhang

  • Jeannie Hou

  • Praveen Bommareddy

  • Robert Coffin

  • Mark Middleton

  • Mohammed Milhem

Medical Centers

  • Norris Comprehensive Cancer Center,Los Angeles,United States

  • Clatterbridge Cancer Centre, Liverpool

  • Churchill Hospital, Oxford,

  • University of Cincinnati, Cincinnati, OH, United States

  • Clínica Universidad de Navarra, New Haven, CT, United States

  • Royal Marsden NHS Foundation Trust & ICR, Sutton, UK

  • Helen Diller Family Comprehensive Cancer, San Francisco, CA, United States

  • James Graham Brown Cancer Center, Louisville, KY, United States

  • West Cancer Center and Research Institute, Germantown, USA

  • Banner MD Anderson Cancer Center, Gilbert, AZ, United States

  • University of California, Los Angeles, Los Angeles, CA

  • Intermountain Medical Center, Murray, United States

  • The Institute of Cancer Research, London, UK

  • University of Leeds, Leeds, UK

  • Weill Cornell Medical College, Medicine, New York, United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03767348

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved